相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
Keiko Takata et al.
SUPPORTIVE CARE IN CANCER (2022)
Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
Antoine Lemaire et al.
SUPPORTIVE CARE IN CANCER (2021)
Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study
Eriko Hiruta et al.
MEDICINA-LITHUANIA (2021)
Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
James Wild et al.
DRUGS & AGING (2020)
Pharmacological Profile of Naldemedine, a Peripherally Acting μ-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol
Toshiyuki Kanemasa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Naldemedine: A Review in Opioid-Induced Constipation
Hannah A. Blair
DRUGS (2019)
Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study
Akihiro Tokoro et al.
CANCER MEDICINE (2019)
Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
Iwao Osaka et al.
ESMO OPEN (2019)
Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
N. Katakami et al.
ANNALS OF ONCOLOGY (2018)
Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes
Tsutomu Suzuki et al.
LIFE SCIENCES (2018)
Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
Ryuji Kubota et al.
PHARMACEUTICAL RESEARCH (2018)
Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline
Stefan Mueller-Lissner et al.
PAIN MEDICINE (2017)
Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer
Nobuyuki Katakami et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer
Nobuyuki Katakami et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
Krzysztof Nosek et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation
A. M. Rentz et al.
JOURNAL OF MEDICAL ECONOMICS (2009)
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dosed of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients
J Hardy et al.
SUPPORTIVE CARE IN CANCER (2002)
分享论文
